Biomea Fusion has released early-stage trial results for BMF-650. Details are in the company's announcement.
Recap by typeshit. Full story at GlobeNewswire.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
Melillo points to a side effect he feels gets too little attention: skin that becomes drier and looks less firm during treatment.
Medical Xpress reports the figure came at the top dose in a trial running about 80 weeks, a key group for Lilly's triple agonist.
Loading…